Medical Affairs Reputations (EU5) [Parkinson's Disease]
|醫療事務相關評價 (歐洲主要5個國家):帕金森氏症 Medical Affairs Reputations (EU5) [Parkinson's Disease]|
|出版日期: 2017年10月01日||內容資訊: 英文||
本報告以歐洲主要5個國家 (EU5:法國·德國·義大利·西班牙·英國) 從事帕金森氏症治療藥開發的醫療團隊為焦點，提供醫生和醫療團隊間的互動性，及主要接觸方法，不同團隊間的業績競爭性評估，今後應該改善項目等相關調查。
How well does your Parkinson's Disease medical affairs team performance compare with the rest?
According to this latest survey of 150 neurologists across the EU5 (UK, France, Germany, Italy and Spain) the performance of Parkinson's Disease medical affairs teams still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.
Use Medical Affairs Reputations: Parkinson's Disease 2017 (EU5) to discover how your team can better meet the high expectations of physicians at the frontline.
This report compares the current activities of medical affairs teams for the 9 leading treatments for Parkinson's Disease from AbbVie, Britannia, GSK, Lundbeck, Meda Pharma, Novartis, Teva, UCB and Zambon. It shows:
It's time to find out exactly how well your medical affairs team is performing against fierce competition - and establish an action plan to gain competitive advantage.
Interested in the US market? Click here to see the US Edition.
Request sample pages
Insight into Medical affairs teams for these Parkinson's Disease treatments
A Competitive View of Your Medical Affairs Team
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of medical affairs teams for 9 leading Parkinson's Disease brands-answering important questions like:
What do physicians need?
Does your medical affairs team deliver?
What needs improvement?
Based on Interviews with Practising Physicians
We surveyed 150 neurologists from the EU5 (France, Italy, Germany, Spain, UK) chosen from the largest community of validated physicians in the world.
We conducted the survey between October 9-25, 2017.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.